Climate Change Data

Environmental Metrics

ESG Focus Areas

• Animal welfare
• Biodiversity
• Business ethics
• Employee well-being
• Employee development
• Environmental impact

Environmental Achievements

• Autoclaving and pyrolysing all glassware, reducing the need for disposable plastics in the R&D phase.
• Diminished use of single-use plastics in cell line development by shifting towards plate-based processes.

Social Achievements

• Adherence to guidelines set by Arbejdstilsynet (Danish Working Environment Authority) for employee well-being, including safety inspections, hazard handling training, and open communication.
• Prioritising comprehensive employee development through funded training opportunities and a flat organizational structure promoting early responsibility and mentorship.

Governance Achievements

• Adherence to corporate governance requirements as a publicly traded company on Nasdaq First North, including compliance with listing requirements, K3 accounting standards, and annual audits.
• Implementation of comprehensive governance policies covering Board procedures, CEO instructions, information and communications, confidentiality, Board minutes, and registration of insider transactions.

Climate Goals & Targets

Environmental Challenges

• Persistent losses affecting valuation and share price.
• Resource constraints limiting large-scale activities.
• Costly development programs.
• Risk of unsuccessful clinical trials and regulatory approvals.
• Competition from larger players.
• Partner failures in obtaining approvals or commercialisation.
• High risk of failure in new biopharmaceutical product development.
• Dependence on key employees.
• Partner dependency.
• Technology dependency (reliance on AdaptVac’s cVLP technology).
• Funding shortfall.
• Increasing burn rate.
• Equity dependency.
• Grant funding uncertainty.
• Limited cVLP platform control.
• Risk of data breaches.
• Freedom to operate (FTO) risks.
• Risk of unwanted side effects or harm to patients during clinical trials.
• Inactive and illiquid share trading and volatile share price.
• Currency risk due to operations in multiple currencies.
• Inflation impacting material and labor costs.

Mitigation Strategies

• Diversifying the development pipeline, prioritizing cost-effective R&D, optimizing resource allocation, strategic collaborations.
• Efficiently managing development costs, exploring funding options and grants, diversifying the product portfolio.
• Robust trial design, collaboration with regulatory agencies, diversifying the candidate portfolio, post-trial data analysis, transparent communication.
• Leveraging unique technology platform, fostering strong relationships with Key Opinion Leaders, continuously monitoring competitor activities.
• Staying informed about the regulatory landscape, planning contingencies for potential setbacks, close collaboration with agencies and authorities.
• Rigorous pre-clinical evaluation and clinical trials, diversifying the product pipeline, collaborating with research partners.
• Offering retention incentives, implementing mentoring and cross-training programs.
• Fostering strong relationships with partners, clearly defining terms in out-licensing agreements, closely monitoring development progress.
• Robust technology transfer processes, investing in internal R&D capabilities, exploring partnerships for technology diversification.
• Diversifying funding sources, optimizing operations to reduce expenses, closely monitoring costs, preparing contingency plans.
• Exploring multiple funding sources beyond grants.
• Close collaboration with AdaptVac, exploring alternative platforms.
• Robust encryption, access controls, regular security audits, staff education on data protection.
• Thorough IP searches, patent landscape analysis, early FTO risk assessment, seeking legal advice.
• Accurate risk assessment during product development, comprehensive clinical trial insurance.
• Enhancing market visibility, actively engaging with investors, regularly communicating company updates, implementing liquidity management strategies, risk communication, insurance coverage, geopolitical risk assessment.
• Majority of cash and equivalents in DKK, contract terms denominated in SEK, evaluating currency risk in new contracts.
• Monitoring price and wage levels, forecasting accurately, inflation clauses in contracts, evaluating alternative suppliers.

Supply Chain Management

Responsible Procurement

• Selecting vendors for animal testing adhering to Global Animal Welfare (GAW), AAALAC, and French Ministry of Agriculture standards.

Climate-Related Risks & Opportunities

Reporting Standards

Frameworks Used: K3

Third-party Assurance: Ernst & Young AB

UN Sustainable Development Goals

• SDG 3: Good Health and Well-being

Developing and deploying effective, safe, cost-efficient, and scalable vaccines to combat a wide range of disorders, from various types of cancer to infectious diseases.